Lexeo Therapeutics: Behind The Rebound
2025-11-06 16:59:15 ET
Shares of gene therapy concern Lexeo Therapeutics, Inc. ( LXEO ) have roughly tripled since a financing in May 2025, partly on the back of FDA alignment on a registrational trial for its LX2006 therapy. Announced on October 7th, its pivotal study for Friederich’s ataxia [FA] cardiomyopathy includes endpoints of left ventricle mass index reduction and frataxin [FXN] levels versus baseline. With other clinical competition in the FA space, including a likely BLA submission from Larimar ( LRMR ) for its FXN protein therapy nomlabofusp in 2026, this small cap biotech firm merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Lexeo Therapeutics: Behind The Rebound
NASDAQ: FA
FA Trading
-2.43% G/L:
$11.225 Last:
416,619 Volume:
$11.50 Open:
